Research
Energy balance
Body weight decreased by 13.3% in patients treated with semaglutide compared to a marginal decrease of -2.6% in placebo-treated patients (P < .001).
Semaglutide can significantly aid in weight loss for obese patients with heart failure.
StrongSupportsmedium confidence
Not surprisingly, body weight decreased marginally in placebo-treated patients (-2.6%), whereas it decreased by 13.3% in patients treated with semaglutide (ETD, -10.7% points; 95% CI, -11.9 to -9.4; P < .001).
Why this rating
The study is a large, double-blind, placebo-controlled trial.
Source
Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction
Giovanna Liuzzo et al. · European Heart Journal · 2023
DOI 10.1093/eurheartj/ehad674
rct · n=529
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).Strong
- Serious adverse events were lower in the semaglutide group (13.3%) compared to the placebo group (26.7%) (P < .001).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →